The global life sciences landscape has become markedly more competitive over the past decade, with investment decisions increasingly driven by a clear set of commercial fundamentals: market scale, speed to revenue and increasingly complex geopolitical factors. While much of the public debate has focused on whether the UK is ‘falling behind’, the reality is more nuanced.

Pharmaceutical companies are not making decisions based on sentiment – they are allocating capital based on where they can achieve the strongest and most sustainable return. In that context, the UK’s challenge is less about capability and more about how well it aligns with the way global pharma now operates. This shift towards more disciplined capital allocation is already evident in our C-suite barometer data, where life sciences leaders report an investment index of just 53% – well below the UK cross-sector average – highlighting a more cautious and selective approach to where and how capital is deployed. In practice, this is leading companies to evaluate investment locations more closely, with much of the recent movement towards the US focused on new facilities and expansion activity rather than wholesale relocation from existing European sites.

Europe’s position in the global life sciences market is being steadily compressed between two increasingly dominant models. In the US, high pricing flexibility and rapid patient access continue to make it the most commercially attractive launch market. At the same time, China is rapidly scaling its innovation ecosystem, supported by state-backed investment, faster clinical trial timelines and a growing domestic market.

Against this backdrop, Europe increasingly risks appearing comparatively fragmented and commercially constrained, particularly as lower drug pricing environments continue to affect investment attractiveness. While it remains a critical region scientifically and commercially, its relative attractiveness for first launches and major investment is under increasing pressure. In reality Europe is rarely being fully deprioritised, but there are clear signs that a growing share of investment capital is being directed towards China, where scale and growth prospects remain highly attractive.

Against this backdrop, Europe increasingly risks appearing comparatively fragmented and commercially constrained, particularly as lower drug pricing environments continue to affect investment attractiveness. While it remains a critical region scientifically and commercially, its relative attractiveness for first launches and major investment is under increasing pressure. In reality Europe is rarely being fully deprioritised, but there are clear signs that a growing share of investment capital is being directed towards China, where scale and growth prospects remain highly attractive.

Within this shifting landscape, the UK’s position has become more exposed following its departure from the European Union. No longer serving as a gateway to the wider EU market, the UK is now assessed more explicitly on its own merits – across regulation, pricing and access. While Brexit has not fundamentally altered how most global firms approach UK launch sequencing, it has sharpened the focus on the specific commercial advantages the UK can offer relative to other markets, particularly around tax incentives, grant support and ease of doing business. The UK nevertheless retains important strengths, including regulatory reliability, strong scientific infrastructure and a geographic position that continues to support international operations.

Pricing in the UK – particularly through NHS mechanisms and rebate schemes – has become a central factor in how the market is perceived globally. Crucially, this is not simply about the absolute price level, but about the signals the system sends to multinational organisations. Low pricing levels and rebate requirements can materially affect revenue expectations, while also influencing international reference pricing in other markets. For global headquarters, UK pricing policy is viewed as a direct indicator of commercial attractiveness, with many organisations continuing to seek stronger pricing potential from the market.

Alongside pricing, the speed at which new medicines reach patients has become an equally critical factor in launch decision-making. Delays between regulatory approval and reimbursement or uptake can significantly reduce the speed at which companies realise value from a market, particularly when managing global launch sequences.

Increasingly, organisations are prioritising countries where they can move quickly from approval to revenue generation, even if pricing is not optimal. In this context, time to access is no longer a secondary consideration – it is becoming a core determinant of competitiveness across all major markets. While the UK remains broadly comparable to other key European markets on speed, maintaining and improving access timelines will remain important to sustaining competitiveness.

Despite these challenges, the UK’s position is far from irrecoverable. The fundamentals – scientific excellence, talent and a strong healthcare system – remain firmly in place. However, improving competitiveness will require a more aligned and commercially coherent approach.

The UK’s challenge in life sciences is often framed as a question of decline, but the reality is more a question of alignment. The country continues to offer many of the capabilities that global pharmaceutical companies value – but its commercial framework does not always reflect how those companies make decisions today.

Addressing that gap does not require wholesale reinvention, but it does demand targeted, practical reform. With the right focus on competitive pricing, targeted investment support and faster market access, the UK can remain a highly competitive player in an increasingly complex global market. The message from industry is clear: the UK remains open for business, but maintaining that position will require government and industry to work together to ensure the market remains financially attractive on a global stage.